摘要
骨关节炎(OA)是一种以关节软骨损害为主要病理改变,可累及滑膜、韧带、软骨下骨及周围骨组织的全关节、异质性疾病,膝骨关节炎(KOA)是OA最常见的一个类型,以疼痛、肿胀、僵硬和功能障碍为主要临床表现,其致残率高,给个人及社会带来沉重的负担。药物干预在KOA的整体管理中占据重要地位,但如何给予KOA患者规范治疗,如何针对患者精准、规范地选择药物仍是临床亟待解决的问题。中国医师协会风湿免疫科医师分会骨关节炎学组依据共识制定国际规范,参考国内外最新的研究证据、相关指南及共识,并综合各领域专家的意见,制定了本共识,涵盖了KOA的预防、治疗目标、临床分型、治疗药物、随访与评估及共病人群的用药六个方面,提出了27条推荐意见,旨在为临床医生安全规范地使用药物提供指引,以提高KOA的诊治水平,使患者获益。
Osteoarthritis(OA)is a heterogeneous disease that involves structural alterations in the articular cartilage,synovium,ligaments,subchondral bone,and the surrounding bone tissue.Among the various types of OA,knee osteoarthritis(KOA)is the most prevalent,presenting with symptoms such as joint pain,swelling,stiffness,and functional limitations.And its high disability rate places a significant burden on both individuals and society.Pharmacological intervention plays a crucial role in the comprehensive management of KOA.However,the establishment of standardized treatment protocols for the accurate and appropriate selection of medications for patients remain pressing clinical challenges.The Osteoarthritis Group of the Rheumatology and Immunology Physicians Branch of the Chinese Medical Doctor Association has developed this expert consensus by drawing upon current research findings,relevant guidelines,and consensus statements from both domestic and international sources.This consensus adheres to international standards for consensus development and incorporates input from a diverse panel of experts.The consensus encompasses six aspects:disease prevention,treatment goals,clinical typing,therapeutic drugs,follow-up and evaluation,and medication for comorbid populations.A total of 27 recommendations are put forward,aiming to provide clinicians with guidance for the safe and standardized use of drugs,thereby improving the diagnosis and treatment level of KOA and benefiting patients.
作者
中国医师协会风湿免疫科医师分会骨关节炎学组
张志毅
曾小峰
代思明
Osteoarthritis Group of the Rheumatology and Immunology Physicians Branch of the Chinese Medical Doctor Association;Zhang Zhiyi;Zeng Xiaofeng(不详;Department of Rheumatology,the First Affiliated Hospital,Harbin Medical University,Harbin 150001,China;,Department of Rheumatology and Clinical Immunology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2024年第6期560-578,共19页
Chinese Journal of Internal Medicine
关键词
骨关节炎
膝
药物治疗
共识
Osteoarthritis,knee
Pharmacological intervention
Consensus
